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Abstract
Background: Patients with sepsis typically require large resuscitation volumes, but the optimal
type of fluid remains unclear. The aim of this systematic review was to evaluate current evidence
on the effectiveness and safety of hydroxyethyl starch for fluid management in sepsis.
Methods: Computer searches of MEDLINE, EMBASE and the Cochrane Library were performed
using search terms that included hydroxyethyl starch; hetastarch; shock, septic; sepsis; randomized
controlled trials; and random allocation. Additional methods were examination of reference lists
and hand searching. Randomized clinical trials comparing hydroxyethyl starch with other fluids in
patients with sepsis were selected. Data were extracted on numbers of patients randomized,
specific indication, fluid regimen, follow-up, endpoints, hydroxyethyl starch volume infused and
duration of administration, and major study findings.
Results: Twelve randomized trials involving a total of 1062 patients were included. Ten trials (83%)
were acute studies with observation periods of 5 days or less, most frequently assessing
cardiorespiratory and hemodynamic variables. Two trials were designed as outcome studies with
follow-up for 34 and 90 days, respectively. Hydroxyethyl starch increased the incidence of acute
renal failure compared both with gelatin (odds ratio, 2.57; 95% confidence interval, 1.13–5.83) and
crystalloid (odds ratio, 1.81; 95% confidence interval, 1.22–2.71). In the largest and most recent
trial a trend was observed toward increased overall mortality among hydroxyethyl starch
recipients (odds ratio, 1.35; 95% confidence interval, 0.94–1.95), and mortality was higher (p <
0.001) in patients receiving > 22 mL·kg-1 hydroxyethyl starch per day than lower doses.
Conclusion: Hydroxyethyl starch increases the risk of acute renal failure among patients with
sepsis and may also reduce the probability of survival. While the evidence reviewed cannot
necessarily be applied to other clinical indications, hydroxyethyl starch should be avoided in sepsis.
Background
Sepsis and its frequent accompaniments – septic shock,
systemic inflammatory response syndrome (SIRS) and
adult respiratory distress syndrome (ARDS) – are major
causes of multiple organ failure and mortality in hospital-
ized patients [1]. Overall hospital mortality rates of 21–
47% have been reported among sepsis patients [2-5].
Acute renal failure (ARF) is a frequent complication [6].
Release of lipopolysaccharide endotoxin from the bacte-
rial cell wall is among the mechanisms believed to initiate
the signs, symptoms and physiologic and biochemical
abnormalities characteristic of septic shock. Maldistribu-
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tion of fluid in the microcirculation is typical of septic
shock and results from endotoxin-induced endothelial
damage. In severe sepsis, acute circulatory failure is often
associated with hypovolemia and inadequate venous
return, cardiac output and tissue nutrient flow [7]. Hypo-
volemia is a significant risk factor for mortality in sepsis
[8], and these patients often require large volumes of
resuscitation fluids [9]. Persistent vasodilation may also
contribute to mortality among patients with sepsis [10].
Due to increased capillary permeability albumin efflux
from plasma to the interstitium is increased three-fold in
septic shock patients [11]. Septic patients frequently
develop hypoproteinemia, which is significantly corre-
lated with fluid retention and weight gain, development
of ARDS and mortality [12].
Colloids are widely used as first-line treatment, in partic-
ular in Europe, usually in combination with crystalloids
[13]. The artificial colloid hydroxyethyl starch (HES) has
gained increasing acceptance for fluid management in a
variety of indications. HES solutions differ according to
their average molecular weight, molar substitution
defined as the proportion of hydroxyethyl units substi-
tuted per glucose monomer, and substitution pattern as
characterized by the ratio of substitution at the C2 and C6
positions on the glucose ring. More rapid clearance of HES
molecules from plasma is observed after infusion of HES
solutions with lower molar substitution, C2/C6 ratio and,
to a smaller extent, molecular weight [14]. Impetus for the
usage of HES has been generated by the higher unit acqui-
sition cost of albumin [15]. Nevertheless, as previously
reviewed [16], safety concerns about HES have been
mounting. Some complications of HES are dose-related,
and sepsis patients may require prolonged fluid adminis-
tration typically with relatively high cumulative volumes.
Consequently, the safety of HES in this indication needs
to be appraised with particular care. The systematic review
presented here is the first to assess randomized clinical tri-
als of HES in sepsis.
Methods
Randomized clinical trials evaluating HES in sepsis were
sought by computer searches of the MEDLINE and
EMBASE bibliographic databases and the Cochrane
Library. Search terms included: hydroxyethyl starch; het-
astarch; shock, septic; sepsis; randomized controlled tri-
als; and random allocation. Additionally, reference lists
were examined and selected specialty journals searched by
hand. Eligibility was not restricted on the basis of trial
endpoints, type of HES solution, time period or language
of publication. Both published and unpublished trials
were eligible for inclusion.
From the trial reports data were extracted on numbers of
patients randomized, specific indication, fluid regimen,
follow-up and endpoints. Extracted data also included the
daily and cumulative HES doses and the duration of HES
administration. Close attention was paid to the investiga-
tors, time periods and trial data to avoid duplication in
case the same trial was the subject of multiple reports and
to ensure completeness of the included evidence in the
event that multiple reports of the same trial contained par-
tially non-overlapping data.
Major findings of the included trials were qualitatively
summarized and tabulated. Due to heterogeneity in the
control regimens, endpoints, length of follow-up and
other trial design features a quantitative meta-analysis was
not judged to be feasible.
Descriptive statistics included the median and interquar-
tile range (IQR). Calculations were performed with R ver-
sion 2.2.1 statistical software (The R Foundation for
Statistical Computing, Vienna, Austria).
Results
Included trials
The selection process for randomized clinical trials is
depicted in Fig. 1. Twelve trials with a total of 1062
patients were included [7,9,17-27]. None was unpub-
lished. With 537 patients, the recent Efficacy of Volume
Substitution and Insulin Therapy in Severe Sepsis (VISEP)
trial accounted for approximately half the patients in the
review [27]. Two included trials were described by Rackow
and co-workers in the 1980s [7,9] and 5 by Boldt et al. in
the 1990s [17-22]. The remaining 5 trials conducted by
various teams of investigators were reported since 2000
[23-27]. One trial in a mixed population of patients with
either septic or non-septic shock was excluded because
septic shock was absent in approximately one-third of the
patients and study endpoint results for septic versus other
forms of shock were reported only in aggregate form
[28,29]. Another trial involving 27 patients with severe
Randomized trial selection process Figure 1







14 trials selected for
possible inclusion in review
12 randomized clinical
trials included
2 trials with aggregated
non-sepsis data excluded
12 trials excluded
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sepsis and 36 with postoperative SIRS was also excluded
due to aggregation of data [30]. Unaggregated data for
that trial were requested from the investigators, but no
response was received.
Trial characteristics
The characteristics of the included trials are summarized
in Table 1. The median number of sepsis patients per trial
was 30 (IQR, 26–64). Only three trials involved more
than 100 patients [22,24,27]. Patients with severe sepsis
or septic shock were enrolled in 6 trials [7,9,24-27]. Of the
6 other trials, 5 involved postoperative sepsis [17-22] and
one sepsis with hypovolemia in ventilated and hemody-
namically controlled patients [23].
HES with a molecular weight of 200 kDa and molar sub-
stitution of 0.5 (HES 200/0.5) was evaluated in 8/12 trials
(67%). HES 200/0.62 was investigated in two trials and
HES 130/0.4 and HES 450/0.7 in one each. The control
fluid was 20% albumin in 6 trials, gelatin in 3, 5% albu-
min in 2 and crystalloid in one.
Ten trials (83%) were acute studies in which the observa-
tion periods ranged from less than 1 h to a maximum of 5
days. Only two trials were designed as outcome studies
with follow-up of 34–90 days.
Cardiorespiratory and hemodynamic variables were end-
points of 7 trials and coagulation parameters of 3. Other
evaluated endpoints consisted of extravascular lung water,
Table 1: Characteristics of included randomized trials
Trial n† Indication Fluid Regimen‡ Follow-Up Endpoints
Falk et al., 1988 [9] 12 Septic shock 6% HES 450/0.7 or 5% 
albumin to 15 mm Hg target 
PAWP
24 h Coagulation
Rackow et al., 1989 [7] 20 Severe sepsis and 
systemic 
hypoperfusion
10% HES 200/0.5 or 5% 
albumin to 15 mm Hg target 
PAWP or 2000 mL maximum
45 min Cardiorespiratory function 
and coagulation
Boldt et al., 1995 [17,18] 30 Sepsis after major 
surgery
10% HES 200/0.5 or 20% 
albumin to 12–16 mm Hg 
target CVP, PCWP or both
5 days Endothelial-related 
coagulation and platelet 
function
Boldt et al., 1996 [19] 30 Sepsis secondary to 
major general surgery
10% HES 200/0.5 or 20% 
albumin to 12–18 mm Hg 
target PCWP
5 days Cardiorespiratory and 
circulatory variables
Boldt et al., 1996 [20] 42 Sepsis secondary to 
major surgery
6% HES 200/0.5, 20% albumin 
or pentoxifylline
5 days Circulating soluble adhesion 
molecules
Boldt et al., 1996 [21] 28 Sepsis secondary to 
major surgery
10% HES 200/0.5 or 20% 
albumin to 10–15 mm Hg 
target PCWP
5 days Circulatory variables
Boldt et al., 1998 [22] 150 Postoperative sepsis 10% HES 200/0.5 or 20% 
albumin to 12–15 mm Hg 
target PCWP
5 days Hemodynamics, laboratory 
data and organ function





500 mL 6% HES 200/0.62 or 
4% succinylated modified fluid 
gelatin
60 min Hemodynamics and gastric 
mucosal acidosis
Schortgen et al., 2001 [24] 129 Severe sepsis or 
septic shock
6% HES 200/0.62 up to 4 days 
or 80 mL·kg-1 cumulative dose 
or 3% gelatin
34 days ARF
Molnár et al., 2004 [25] 30 Septic shock with 
hypovolemia and 
acute lung injury
6% HES 200/0.5 or 4% 
modified fluid gelatin to 
achieve ITBVI > 900 mL·m-2
60 min Hemodynamics, EVLW and 
oxygenation
Palumbo et al., 2006 [26] 20 Severe sepsis in 
mechanically 
ventilated patients
6% HES 130/0.4 or 20% 
albumin to maintain PCWP of 
15–18 mm Hg
5 days Hemodynamic and 
oxygenation parameters
Brunkhorst et al., 2008 [27] 537 Severe sepsis or 
septic shock
10% HES 200/0.5 (to 20 
mL·kg-1·day-1 limit) or Ringer's 
lactate to target of ≥ 8 mm 
Hg CVP
90 days Morbidity and mortality
Abbreviations: ARF, acute renal failure; CVP, central venous pressure; EVLW, extravascular lung water; HES, hydroxyethyl starch; ICU, intensive 
care unit; ITBVI, intrathoracic blood volume index; PAWP, pulmonary arterial wedge pressure; PCWP, pulmonary capillary wedge pressure
†For trials with more than one indication, includes only patients with sepsis.
‡HES solutions specified by molecular weight/molar substitution.BMC Emergency Medicine 2008, 8:1 http://www.biomedcentral.com/1471-227X/8/1
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gastric mucosal acidosis, circulating soluble adhesion
molecules, ARF and morbidity and mortality.
HES posology
Patients in the included trials received HES for a median
of 5 days (IQR, 1–5 days). The median daily HES dose was
12.6 mL·kg-1 (IQR, 11.0–13.7 mL·kg-1) and the median
cumulative dose 49.8 mL·kg-1 (IQR, 22.6–63.0 mL·kg-1).
Major findings
Hemodynamic and cardiorespiratory variables were
improved by HES 130/0.4 and HES 200/0.5 compared
with 20% albumin [19,22,26] but not gelatin [25]. Acute
Physiology and Chronic Health Evaluation (APACHE) II
score was also improved by HES 130/0.4 but not 20%
albumin [26]. HES 200/0.5 either improved gastric intra-
mucosal pH (pHi) compared with 20% albumin [21] or
avoided a decline in pHi observed in 20% albumin recip-
ients [19]. On the other hand, gelatin raised pHi and
decreased CO2  gastric mucosal arterial gradient, while
HES 200/0.62 did not display these beneficial effects [23].
HES 450/0.7 impaired coagulation, as judged by pro-
longed partial thromboplastin time, and decreased plate-
let count [9]. These undesirable effects were not
encountered in patients receiving 5% albumin. HES 200/
0.5 diminished factor VIII levels compared with 5% albu-
min [7]. Differences in coagulation and platelet count
between HES 200/0.5 and 20% albumin were not
observed in one trial [22]. Compared with crystalloid,
HES 200/0.5 interfered with coagulation as indicated by a
higher sequential organ failure assessment (SOFA) coagu-
lation subscore (p < 0.001) and greater median red blood
cell transfusion requirement of 6 units (IQR, 4–12 units)
vs. 4 units (IQR, 2–8 units) for the control group (p <
0.001) [27].
In a trial of 129 patients with severe sepsis or septic shock
by Schortgen et al. [24], the groups randomized to receive
HES 200/0.62 or gelatin were similar at baseline in sever-
ity of illness and serum creatinine. However, over the 34
day study observation period the incidence of ARF was
increased in the HES 200/0.62 recipients (p = 0.018). In a
multivariate analysis with adjustment for fluid loading
before inclusion and mechanical ventilation at inclusion,
HES 200/0.62 exposure was shown to be an independent
risk factor for ARF (Table 2). At the conclusion of the
study, ARF incidence in the HES 200/0.62 group (61%)
exceeded that in the gelatin group (31%) by 30% based
on Kaplan-Meier analysis. The median time to ARF among
patients receiving HES 200/0.62 was 16 days. An earlier
trial by Boldt and co-workers [22] failed to detect an effect
of HES 200/0.5 on incidence of renal failure, possibly as a
result of the short 5 day observation period. In the trial of
Schortgen et al., a between-group difference in ARF inci-
dence of only 11% was evident at the 5 day time point.
The recent multicenter VISEP trial assessing morbidity and
mortality up to 90 days in 537 patients with severe sepsis
or septic shock is the first large-scale outcome study of
HES 200/0.5 in any clinical indication [27]. The HES 200/
0.5 and crystalloid groups were well-matched at baseline
in severity of illness and serum creatinine. HES 200/0.5
infusion compromised renal function (p = 0.02) as
reflected by a higher SOFA renal subscore than that of the
control group. The incidence of ARF and use of renal
replacement therapy (RRT) were both increased by HES
200/0.5 (Fig. 2). RRT usage was positively correlated with
cumulative HES 200/0.5 dose (p < 0.001). Even in the
subset of patients receiving exclusively lower HES 200/0.5
doses (≤ 22 mL·kg-1), higher ARF incidence (p = 0.04)
and RRT utilization (p = 0.03) were demonstrated in com-
parison with the crystalloid control group.
In the VISEP trial there was also an overall trend toward
increased mortality among HES 200/0.5 recipients (Fig.
2). Mortality at 90 days was correlated with cumulative
HES 200/0.5 dose (p = 0.001) and significantly increased
(p < 0.001) in patients receiving > 22 mL·kg-1 HES 200/
0.5 (58%) for at least one day than lower doses (31%).
Discussion
Until relatively recently, randomized trial evidence con-
cerning HES for fluid management in sepsis patients has
stemmed almost entirely from small acute studies, often
focused on cardiorespiratory and hemodynamic end-
points. These trials were thus not designed to evaluate
safety or outcomes, and renal function in particular was
not evaluated. The report of Schortgen et al. [24] was to
first to raise serious concern that HES might adversely
affect renal function in sepsis. The results of that trial
should perhaps have been unsurprising in light of earlier
randomized trials indicating deleterious effects of HES on
the kidney in cardiac [31] and abdominal surgery [32] and
renal transplantation [33]. The VISEP trial [27] has now
furnished convincing confirmation that HES increases
ARF incidence in sepsis.
The administration of HES 200/0.5 in the VISEP trial has
also put to rest the argument that the adverse renal effects
observed by Schortgen et al. might have been due to their
use of the more highly substituted HES 200/0.62 solution.
On the other hand it should be recognized that the results
of sepsis trials involving repeated HES infusion over a
period of several days or more cannot necessarily be
extrapolated to other settings such as postoperative fluid
management involving lower HES doses for a shorter
time.BMC Emergency Medicine 2008, 8:1 http://www.biomedcentral.com/1471-227X/8/1
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The VISEP trial has also provided the first evidence that
HES may increase mortality among sepsis patients. A
trend toward higher mortality was observed among all
recipients of HES compared with crystalloid, and mortal-
ity was significantly increased by higher HES doses. These
data are in contrast to the results of the SAFE trial [34]
comparing 4% albumin with normal saline. In the subset
of 1218 SAFE trial patients with severe sepsis, a trend
toward reduced mortality was evident in the albumin
group (odds ratio, 0.81; 95% confidence interval, 0.63–
1.04; p = 0.09). In light of these disparate survival trends,
a need exists for an adequately powered outcome trial
directly comparing HES and albumin in sepsis.
Schortgen et al. detected no effect of HES 200/0.62 on sur-
vival; however, the duration of follow-up in their trial was
34 days. In the VISEP trial the Kaplan-Meier survival
curves for the two randomized groups began to diverge
only at approximately 30 days and were clearly separated
thereafter. It is thus possible that in the trial of Schortgen
Table 2: HES dose administered and major findings of included randomized trials
Trial Days on HES Mean mL·kg-1 HES Major Findings
Daily Cumulative
Falk et al., 1988 [9] 1 70.5† 70.5† In HES 450/0.7 group PTT increased by 20 s (p = 0.01) and platelet count 
decreased by 158 × 103 mm-3 (p = 0.01); no significant PTT or platelet 
count change in albumin group
Rackow et al., 1989 [7] 1 12.9† 12.9† FVIII:c declined 45% in the HES 200/0.5 group compared with 5% in the 
albumin group (p = 0.05)
Boldt et al., 1995 [17,18] 5 8.5 42.3 Plasma thrombomodulin increased in the albumin group and remained 
unchanged in the HES 200/0.5 group (p < 0.05); plasma protein C among 
HES 200/0.5 recipients increased on days 4 and 5 without corresponding 
change in the albumin group (p < 0.05); maximum platelet aggregation 
declined in both groups (p < 0.05)
Boldt et al., 1996 [19] 5 11.0 55.2 HES 200/0.5 but not albumin increased cardiac index, RVEF, Pao2/Fio2, Do2I 
and Vo2I and decreased SVRI (p < 0.05 for all comparisons); pHi decreased 
in albumin but not HES 200/0.5 group (p < 0.05)
Boldt et al., 1996 [20] 5 12.7 63.7 Circulating sELAM-1 and sICAM-1 concentrations reduced by HES 200/0.5 
compared with albumin (p < 0.05 for both comparisons)
Boldt et al., 1996 [21] 5 11.0 49.8 Vasopressin, endothelin-1 and norepinephrine decreased and pHi increased 
in HES 200/0.5 but not albumin group (p < 0.05 for all comparisons); ANP 
increased by albumin but not HES 200/0.5 (p < 0.05)
Boldt et al., 1998 [22] 5 12.5 62.4 Pao2/Fio2, Do2I and Vo2I increased and lactate decreased by HES 200/0.5 
but not albumin (p < 0.05 for all comparisons); no differences in incidence 
of renal failure, platelet count, PT or aPTT
Asfar et al., 2000 [23] 1 7.9 7.9 Gelatin but not HES 200/0.62 increased pHi (p < 0.001) and decreased CO2 
gastric mucosal arterial gradient (p < 0.0005)
Schortgen et al., 2001 [24] 4‡ 14.0‡ 31.0‡ HES 200/0.62 exposure an independent risk factor for ARF (adjusted odds 
ratio, 2.57; CI 1.13–5.83)
Molnár et al., 2004 [25] 1 14.3† 14.3† No differences detected in ITBVI, EVLW or Pao2/Fio2
Palumbo et al., 2006 [26] 5 --§ --§ Target PCWP of 15–18 mm Hg maintained by both colloids; temperature, 
MAP, PAP, CVP, heart rate and urine output remained stable without 
differences between groups; HES 130/0.4, but not albumin, increased 
cardiac index and several oxygenation parameters (Pao2/Fio2, Do2I and 
Vo2I) and decreased APACHE II score (p < 0.05 for all within-group 
comparisons)
Brunkhorst et al., 2008 [27] 21 --§ 70.4¶ Greater ARF incidence in HES 200/0.5 group (odds ratio, 1.81; CI, 1.22–
2.71; p = 0.002); increased mortality at higher HES 200/0.5 doses (odds 
ratio, 3.08; CI, 1.78–5.37; p < 0.001)
Abbreviations: ANP, atrial natriuretic peptide; APACHE, Acute Physiology and Chronic Health Evaluation; aPTT, activated partial thromboplastin 
time; ARF, acute renal failure; CI, 95% confidence interval; CVP, central venous pressure; Do2I, oxygen delivery index; EVLW, extravascular lung 
water; HES, hydroxyethyl starch; FVIII:c, factor VIII coagulant activity; ITBVI, intrathoracic blood volume index; MAP, mean arterial pressure; Pao2/
Fio2, ratio of partial pressure of arterial oxygen to fraction of inspired oxygen; PAP, pulmonary artery pressure; PCWP, pulmonary capillary wedge 
pressure; pHi, gastric intramucosal pH; PT, prothrombin time; PTT, partial thromboplastin time; RVEF, right ventricular ejection fraction; sELAM-1, 
soluble endothelial leucocyte adhesion molecule-1; sICAM-1, soluble intercellular adhesion molecule-1; SVRI, systemic vascular resistance index; 
Vo2I, oxygen consumption index
†Calculated from reported volume administered assuming 70 kg body weight.
‡Actual days on HES not specified. Maximum of 4 days imposed after start of study, and percentage of patients receiving HES longer not indicated. 
Daily dose stated for day 1 only. Cumulative dose reported as median.
§Not reported.
¶Median.BMC Emergency Medicine 2008, 8:1 http://www.biomedcentral.com/1471-227X/8/1
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et al. a mortality difference might have become apparent
with longer follow-up.
The mechanisms that might account for undesirable HES
effects on kidney function and possibly survival in sepsis
are not understood. One putative mechanism is renal
ischemia [24]. HES has been shown to increase plasma
viscosity in vitro compared with albumin [35]. In a rat
model of severe hemorrhagic shock, both 6% HES and
5% albumin restored macrocirculatory function as meas-
ured by mean arterial pressure [36]. However, only albu-
min completely returned mesenteric microcirculatory
blood flow to the baseline level. Furthermore, albumin
was effective in restoring mesenteric lymphatic output,
while HES was not (p < 0.05).
Since more than 30 years ago there has been evidence that
HES might impair reticuloendothelial system (RES) func-
tion, thereby impairing host defenses against sepsis and
possibly contributing to multiple organ failure, including
ARF, and mortality [37]. A substantial proportion of
administered HES cannot be metabolized acutely and
undergoes uptake and storage by the RES, most notably in
macrophages including those localized in the kidney [38-
42]. In a quantitative necropsy specimen study of 12
young adult patients who had died due to sepsis and
multi-organ failure after receiving a mean of 258 mL·day-
1 HES 200/0.5, the highest mean major organ HES tissue
concentration was measured in the kidney (13.7 mg·g-1)
[43]. The effects of plasma substitutes on RES function in
mice were investigated by intraperitoneal injection of Sal-
monella enteritidis endotoxin [37]. Host defenses against
this endotoxin are mediated by RES macrophages. Prior
infusion of HES but not plasma increased the lethality of
endotoxin injected either 1 h (p < 0.05) or 3 h (p < 0.01)
subsequently. Similarly, in a murine hemorrhagic shock
model no HES-resuscitated animal survived intraperito-
neal injection of live E. coli at 1 h after resuscitation,
whereas survival with shed blood resuscitation was 64%
[44]. In contrast to these two studies involving acute septic
challenge within 1–3 h after HES administration, a
delayed challenge in the form of cecal ligation and punc-
ture 48 h after HES infusion did not increase mortality in
rats [45]. In any case, there is at present no clinical evi-
dence indicating HES-mediated impairment of RES func-
tion in sepsis, and clinical studies will be required to
delineate the role, if any, of the RES in explaining the
observed deleterious effects of HES among septic patients.
A variety of HES solutions are available that differ in aver-
age molecular weight, molar substitution, C2/C6 ratio
and solvent. It has often been claimed that a particular
HES solution may be devoid of safety problems displayed
by others. Several recent evidence-based reviews have
challenged this contention [16,46-48]. Similar types of
complications, including impaired kidney function [48],
have been encountered clinically across the entire spec-
trum of HES solutions. These adverse effects appear to
reflect the intrinsic pharmacologic properties of the HES
molecule rather than differences between individual HES
solutions [49]. For instance, HES 130/0.4 was shown to
impair renal function assessed by four sensitive markers in
a randomized trial of elderly cardiac surgery patients [50].
HES 450/0.7 in Ringer's lactate vehicle was independently
associated with reduced glomerular filtration rate in a ret-
rospective study of 238 consecutive coronary artery bypass
graft patients [51]. The safety of either solution for fluid
management in sepsis would need to be demonstrated in
clinical trials.
Incidence of acute renal failure, use of renal replacement therapy and mortality in patients receiving HES or crystalloid Figure 2
Incidence of acute renal failure, use of renal replacement therapy and mortality in patients receiving HES or crystalloid. Abbre-
viations: CI, 95% confidence interval; HES, hydroxyethyl starch. Based on the data of Brunkhorst et al. [27].
Endpoint Number of Patients Odds Ratio (CI) p
HES Crystalloid
Yes No Yes No
Acute Renal Failure 91 170 62 210 1.81 (1.22-2.71) 0.002
Renal Replacement Therapy 81 180 51 221 1.95 (1.28-2.98) 0.001
Mortality 107 154 93 181 1.35 (0.94-1.95) 0.11
Odds Ratio
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Conclusion
Compelling evidence is now at hand indicating that HES
infusion places sepsis patients at increased risk for ARF.
New data also suggest the possibility of poorer survival
among sepsis patients receiving HES, especially higher
doses. Clearly, HES 200/0.5 and HES 200/0.62 cannot
now be recommended in sepsis. The effectiveness and
safety of other HES solutions in this indication remain to
be determined in future clinical trials.
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